An in silico evaluation of CDK Inhibitors targeting BCL2, TS and mTOR
Keywords:Cyclin dependent kinases; cell cycle; BCL2; TS; mTOR; amebaciclib; palbociclib
The cyclin dependent kinase (CDK) inhibitors have recently been found to be of potential use as anticancer drugs. The present research work focuses on screening of compounds targeting multiple pathways involved in human cancers along with CDK-regulated cell cycle for prospective anticancer potential. Molecular docking study of selected compounds were performed to determine the binding affinity of selected compounds towards respective targets of cancer cells to verify if there is any physical interaction of these inhibitors with their reported target proteins as claimed in the existing literatures. Prior to docking, molecular pathway prediction and gene set enrichment analyses were performed to identify the target molecules by using appropriate bioinformatics tools. Interestingly, the results of in silico molecular docking have been found to be in line with the laboratory findings that are obtained from the literatures. Specifically, few of our selected CDK inhibitors, namely Abemaciclib, Palbociclib, AMG 925 and RGB 286638 showed good binding scores against BCL2, TS, mTOR in addition to CDKs (4, 6 and 9). On the basis of scientific evidence based on published scholarly articles and according to molecular docking results, it can be inferred that these CDK inhibitors as anticancer agents may play a very promising role in cancer treatment and can be used as potential lead compounds for the development of target therapy against human cancers. However, more intensive research is needed to confirm the feasibility of these compounds to be used in treating cancer and it is expected that this work will provide a stimulating impetus for the development of chemotherapeutic agents in future.
Asian J. Med. Biol. Res. 2021, 7 (2), 126-131
How to Cite
Copyright (c) 2021 Sharmin Ahmed Rakhi, Muhammad Asaduzzaman, Nishat Nasin and Abul Bashar Mir Md Khademul Islam
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms / The author(s) affirm(s) that:
- The manuscript submitted is based on authors own research and is original work.
- Authors certify that we all participated in the research work and preparation of the manuscript in a substantive way.
- Authors also declare that they have read and approved the manuscript.
- Authors further declare that the manuscript has not been published in part or full and is not being submitted or considered for publication in part or full elsewhere.
- Any material included in the manuscript does not violate copyright or other rights of anyone.
- Authors also affirm that the article contains no vilifying or unlawful statements and does not contain material or instructions that might cause harm or injury to the Editor-in-Chief/Editors of the Journal and the public.
- Authors assure Asian J. Med. Biol. Res. and the Editor-in-Chief/Editors of the Journals, and hold them harmless from any loss, expense or damage occurred by a claim or suit by a third party for copyright violation, or any suit arising out of any violation of the foregoing warranties as a result of publication of my/our article.
- In consideration of authors manuscript submitted, authors hereby grant Asian J. Med. Biol. Res. unlimited, worldwide, permanent royalty-free, right to publish, use, dispense, license, transmit, display, exhibit, record, store, translate, digitize, broadcast, reproduce and archive, in any format or medium, whether now known or developed hereafter.
All materials related to manuscripts, accepted or rejected, including photographs, original figures etc., will be kept by Asian J. Med. Biol. Res. for one year following the editors decision. These materials will then be destroyed.